199 related articles for article (PubMed ID: 2818677)
1. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
3. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
4. The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells.
Kawamura I; Lacey E; Mizota T; Tsujimoto S; Nishigaki F; Manda T; Shimomura K
Anticancer Res; 1994; 14(2A):427-31. PubMed ID: 8017842
[TBL] [Abstract][Full Text] [Related]
5. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
Gao HD; Sun JZ; Bi DS; Ma R
Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
[TBL] [Abstract][Full Text] [Related]
6. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.
Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528
[TBL] [Abstract][Full Text] [Related]
7. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological activities of droloxifene isomers.
Löser R; Seibel K; Huber HJ
Anticancer Res; 1988; 8(6):1271-4. PubMed ID: 3218958
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
10. Preclinical data for Droloxifene.
Hasmann M; Rattel B; Löser R
Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
[TBL] [Abstract][Full Text] [Related]
11. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
[TBL] [Abstract][Full Text] [Related]
12. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
Yu Y; Zhou Q; Hang Y; Bu X; Jia W
Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948
[TBL] [Abstract][Full Text] [Related]
14. Antitumor mechanism of action of a cyclopropyl antiestrogen (compound 7b) on human breast cancer cells in culture.
Jain PT; Pento JT; Magarian RA
Cancer Chemother Pharmacol; 1996; 38(3):238-44. PubMed ID: 8646798
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
17. Basic guide to the mechanisms of antiestrogen action.
MacGregor JI; Jordan VC
Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
19. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
20. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
